Teclistamab solution for injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Others

Brand
Tecvayli
Company
Janssen-Cilag International NV (EU authorization holder)
Medicine type
Biologic
Therapeutic area
Oncology
Indications recorded in the public source
EU: With daratumumab for adults with relapsed or refractory multiple myeloma after at least one prior therapy. Used alone for adults with relapsed and refractory disease progressing on the last treatment after at least three therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
Indication source and scope
EU product information updated 2026-08-27. Selected overseas indications; does not establish the Chinese approved scope.
Prescribing-information limitations
Overseas official prescribing information linked; a complete current Chinese label has not been verified.
China availability status
Chinese approval, locally approved indications and current availability have not been independently verified in this import.
Overseas status
See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
Insurance classification
Not yet verified
Insurance edition
Chinese national insurance review pending
Insurance verification notes
No reimbursement determination was made for this addition; missing information is not proof of exclusion.

Sources

Evidence reviewed:

Open the interactive record, public price references and discussions